CKB News Archive

  • 2018
    • December
      • NEW! CKB CORE users will be exposed to more gene content on a quarterly rotating basis. This month we highlight ARID1A and will return EGFR and PIK3CA later in 2019. These genes are always accessible in CKB BOOST
  • 2018
    • November
      • Vitrakvi (larotrectinib) approved regardless of tumor type for NTRK fusions, except with acquired resistance mutations! Need a list of resistance mutations? Visit and sign-up for CKB BOOST.
  • 2017
    • October
      • Barriers preventing the adoption of comprehensive cancer genomic profiling in the clinic (PMID: 28402162). Limited free copies available; request your copy at